Oral PHA-022121 extension for hereditary angioedema attacks
Treatments studied
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian if under 18) sign consent, and older teens may need to assent.
- You must have taken study drug in a previous related study (or be a specific eligible adolescent who completed it).
- If you can become pregnant: agree to pregnancy tests and use approved contraception (or avoid heterosexual intercourse) until 30 days after your last dose.
- You must be able/willing to follow all study instructions and attend visits.
- You must have HAE type III (HAE-nC1INH) and meet special lab and diagnosis rules, including C1 inhibitor function and C4 blood level results.
- Your attacks must have not improved with certain other medicines, and you must have proven relief with on-demand icatibant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a daily oral tablet called deucrictibant to see if it can prevent swelling attacks in people with hereditary angioedema (HAE). If you join, you will take the study drug for a longer period and track your symptoms in a diary.
This expanded access program offers an investigational medication called deucrictibant immediate-release to people with hereditary angioedema (HAE) who have no good treatment options for their acute attacks. It aims to provide relief when other approved therapies haven't worked or aren't suitable.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This trial lets children who already took part in a previous CSL312 study for hereditary angioedema continue receiving the medicine. It helps ensure they don't have a gap in treatment while longer-term safety and effects are monitored.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
Hear when a new Hereditary Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.